Ascendis Pharma A/S granted 29,380 warrants to employees on September 8, 2026, with each Warrant covering one ordinary share at an exercise price of US $270.09. The grant matters to investors because it establishes the terms for employee share subscriptions while leaving warrants covering 1,495,063 additional shares available for future grants.

Key Highlights

  • Warrants covering 1,495,063 additional shares remain available for future grants.
  • Ascendis Pharma A/S granted 29,380 warrants to certain employees on September 8, 2026.
  • The exercise price equals the closing price of Ascendis Pharma A/S ordinary shares reported on the grant date, with earlier vesting possible upon certain exit events.
  • After the grant, 1,495,063 shares remained available for future warrant issuance under the Articles of Association; 13,665,720 warrants had been issued under the listed authorizations, of which 9,057,394 had been exercised, annulled or lapsed as of September 8, 2026.

Ascendis Pharma A/S (NASDAQ: ASND) granted 29,380 warrants to certain employees on September 8, 2026.

Employee Warrant Terms

Earlier vesting can occur if certain exit events take place. The exercise price is equal to the closing price of Ascendis Pharma A/S ordinary shares reported on the grant date.

Future Grant Capacity

After the grant, warrants covering 1,495,063 additional shares remain available for future issuance by the board under the Articles of Association. The company’s Share Capital is DKK 66,380,466. The amended articles state that 13,665,720 warrants have been issued under the listed authorizations, of which 9,057,394 had been exercised, annulled or had lapsed as of September 8, 2026.

Articles Amended

The grant was made under Appendix 1a to Ascendis Pharma A/S’s Articles of Association. The amended articles provide for the employee warrants and set out the related subscription rights. The company signed the report on September 9, 2026 through Michael Wolff Jensen, Executive Vice President and Chief Legal Officer.